CN118593509A - Application of non-gotinib as sensitizer of anti-triple negative breast cancer drug BBDI - Google Patents
Application of non-gotinib as sensitizer of anti-triple negative breast cancer drug BBDI Download PDFInfo
- Publication number
- CN118593509A CN118593509A CN202410809482.9A CN202410809482A CN118593509A CN 118593509 A CN118593509 A CN 118593509A CN 202410809482 A CN202410809482 A CN 202410809482A CN 118593509 A CN118593509 A CN 118593509A
- Authority
- CN
- China
- Prior art keywords
- breast cancer
- negative breast
- triple negative
- bbdi
- cancer drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 title claims abstract description 112
- 208000022679 triple-negative breast carcinoma Diseases 0.000 title claims abstract description 109
- RKFZTABXZXYIOJ-UHFFFAOYSA-N tert-butyl 1-[(2-methylpropan-2-yl)oxy]-1h-isoquinoline-2-carboxylate Chemical compound C1=CC=C2C(OC(C)(C)C)N(C(=O)OC(C)(C)C)C=CC2=C1 RKFZTABXZXYIOJ-UHFFFAOYSA-N 0.000 title claims abstract 20
- 239000003560 cancer drug Substances 0.000 title claims description 53
- 239000003814 drug Substances 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 102100023410 Phospholipid hydroperoxide glutathione peroxidase Human genes 0.000 claims description 59
- 239000008194 pharmaceutical composition Substances 0.000 claims description 38
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 20
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 20
- 229960004836 regorafenib Drugs 0.000 claims description 20
- 230000002018 overexpression Effects 0.000 claims description 19
- 230000035945 sensitivity Effects 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 claims 2
- 230000002500 effect on skin Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- DNVXATUJJDPFDM-UHFFFAOYSA-N LSM-6732 Chemical compound C1=2C(C)=C(C)SC=2N2C(C)=NN=C2C(CC(=O)OC(C)(C)C)N=C1C1=CC=C(Cl)C=C1 DNVXATUJJDPFDM-UHFFFAOYSA-N 0.000 abstract description 13
- 206010018498 Goitre Diseases 0.000 abstract description 4
- 201000003872 goiter Diseases 0.000 abstract description 4
- 230000002147 killing effect Effects 0.000 abstract description 4
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- DNVXATUJJDPFDM-KRWDZBQOSA-N JQ1 Chemical compound N([C@@H](CC(=O)OC(C)(C)C)C1=NN=C(N1C=1SC(C)=C(C)C=11)C)=C1C1=CC=C(Cl)C=C1 DNVXATUJJDPFDM-KRWDZBQOSA-N 0.000 description 72
- 108010033024 Phospholipid Hydroperoxide Glutathione Peroxidase Proteins 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 50
- 239000000203 mixture Substances 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 101150041639 GPX4 gene Proteins 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000005757 colony formation Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- -1 small molecule compound Chemical class 0.000 description 6
- 102100026662 Delta and Notch-like epidermal growth factor-related receptor Human genes 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 5
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 229940125763 bromodomain inhibitor Drugs 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000030279 gene silencing Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 4
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- AAAQFGUYHFJNHI-SFHVURJKSA-N 2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(OC)C=C11)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 AAAQFGUYHFJNHI-SFHVURJKSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- GCWIQUVXWZWCLE-INIZCTEOSA-N pelabresib Chemical compound N([C@@H](CC(N)=O)C=1ON=C(C=1C1=CC=CC=C11)C)=C1C1=CC=C(Cl)C=C1 GCWIQUVXWZWCLE-INIZCTEOSA-N 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108091005625 BRD4 Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 229950000080 birabresib Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000001805 Bromodomains Human genes 0.000 description 1
- 108050009021 Bromodomains Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Chemical class 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 240000004153 Hibiscus sabdariffa Species 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Chemical class 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012526 feed medium Substances 0.000 description 1
- 229950006663 filgotinib Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000012174 single-cell RNA sequencing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of non-goiter as a sensitizer of a triple negative breast cancer resistant medicament BBDI, and discovers that the non-goiter can be used as a sensitizer of a triple negative breast cancer resistant medicament BBDI (JQ 1) for the first time, enhances cytotoxicity and killing effect of the triple negative breast cancer resistant medicament JQ1 on tumor cells, has good potential of developing the triple negative breast cancer resistant medicament JQ1 sensitizer, and provides a brand-new thought and strategy for developing the triple negative breast cancer treatment medicament, thereby having good clinical application prospect.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to an application of non-gotinib as a sensitizer of a triple negative breast cancer resistant drug BBDI, wherein the triple negative breast cancer resistant drug BBDI is JQ1.
Background
Triple negative breast cancer (TRIPLE NEGATIVE breast cancer, TNBC) accounts for about 15% -20% of all breast cancer patients, is the most invasive subtype in breast cancer, has high mortality and is easy to relapse. Characterized by the lack of expression of Estrogen Receptor (ER) and Progesterone Receptor (PR) and by the lack of human epidermal growth factor receptor 2 (HER 2) amplification. Cancer genomic sequencing studies focused on triple negative breast cancers fail to find new repeatedly mutated oncogenes, and thus cannot immediately develop targeted therapies. Furthermore, triple negative breast cancer is also a heterogeneous disease, indicating that one treatment may not be appropriate for all patients and that multiple new treatment strategies are required. Thus, there is a need for new treatment regimens for triple negative breast cancer.
Currently, chemotherapy is one of the most common treatments for triple negative breast cancer, however, 60% -70% of triple negative breast cancer patients do not show a good response to chemotherapy. BET bromodomain inhibitors (BBDI) are considered potential candidate therapeutic agents for the treatment of triple negative breast cancers in preclinical studies and clinical trials. JQ1, as classical BBDI, can shorten BRD4 communication and transcription of downstream oncogenes, thereby generating selective transcriptional responses and antiproliferative effects in solid tumor and hematological malignancy models, killing tumor cells. However, the clinical use of JQ1 is greatly limited by resistance. Thus, understanding the underlying mechanisms of BBDI resistance contributes to the effective treatment of triple negative breast cancers.
Disclosure of Invention
In view of the above, in order to solve the technical problems faced in the prior art, the invention aims to provide the application of the regorafenib as the sensitizer of the anti-triple negative breast cancer drug BBDI, the regorafenib is firstly adopted as the sensitizer of the anti-triple negative breast cancer drug BBDI (JQ 1), the sensitivity of triple negative breast cancer cells to the JQ1 drug is improved, and the curative effect of the triple negative breast cancer can be remarkably improved by the combination of the regorafenib and the JQ 1.
The above object of the present invention is achieved by the following technical solutions:
the first aspect of the invention provides the use of regorafenib in the preparation of a sensitizer for an anti-triple negative breast cancer drug BBDI.
Further, the anti-triple negative breast cancer drug BBDI is JQ1, and the structural formula of JQ1 is shown in formula (I):
Formula (I).
Further, the non-goiter is capable of increasing the sensitivity of triple negative breast cancer cells to the anti-triple negative breast cancer drug BBDI.
Further, overexpression of GPX4 in triple negative breast cancer cells results in its resistance to the triple negative breast cancer drug BBDI.
Further, the concentration ratio of the regorafenib and the anti-triple negative breast cancer drug BBDI is (40 μm-320 μm): (5. Mu.M-50. Mu.M).
In the present invention, the anti-triple negative breast cancer drug BBDI refers to a BET bromodomain inhibitor (BET bromodomain inhibitor, BBDI), which is a candidate therapeutic agent for triple negative breast cancer and other types of cancer, but the inherent and acquired resistance to BBDI limits its potential clinical application, so that research on the drug resistance mechanism of BBDI and finding an optimal combination drug regimen (for example, a combination drug regimen for increasing BBDI drug sensitivity) are technical problems that need to be solved when BBDI is applied to clinical treatment of triple negative breast cancer and other types of cancer at present.
In some embodiments, the anti-triple negative breast cancer drug BBDI includes, but is not limited to: JQ1, TEN-010, OTX-015, I-BET762, CPI-0610, wherein JQ1 is the first reported BET inhibitor with a short half-life; TEN-010 and OTX-015 are both five-membered and seven-membered and five-membered tricyclic skeletons, and the molecular structure is characterized by different substituents on the amide nitrogen; both I-BET762 and CPI-0610 are five-membered and seven-membered and six-membered tricyclic backbones, the five-membered ring of I-BET762 is triazole, and the five-membered ring of CPI-0610 is isoxazole. In a specific embodiment of the invention, the anti-triple negative breast cancer drug BBDI is JQ1.
In the invention, JQ1 is BET bromodomain inhibitor, the molecular formula is C 23H25ClN4O2 S, the molecular weight is 456.988, the structural formula is shown as the formula (I), and the IC50 for inhibiting BRD4 (1/2) is 77 nM and 33 nM respectively. The corresponding Chinese names are: (S) - (+) -2- (4- (4-chlorophenyl) -2,3, 9-trimethyl-6H-thieno [3,2-f ] [1,2,4] triazolo [4,3-a ] [1,4] diazepin-6-yl) acetic acid tert-butyl ester corresponding to the English name :(S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate.
In the present invention, the non-golitinib (Filgotinib) is an oral, ATP-competitive, reversible JAK1 inhibitor for the treatment of inflammatory autoimmune diseases, including inflammatory arthritis and inflammatory bowel disease. JAK-STAT signaling pathway is involved in the pathogenesis of inflammatory and autoimmune diseases, and regoratinib regulates this pathway by preventing STAT phosphorylation and activation. Clinical trial indications for non-golitinib include crohn's disease, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus and the like. There is no study or report on the use of regorafenib as a sensitizer for the anti-triple negative breast cancer drug BBDI (JQ 1).
In a specific embodiment of the invention, the experiment proves that GPX4 over-expression leads to the drug resistance of triple negative breast cancer cells to JQ1, the non-gotinib alone has no obvious inhibition effect on the triple negative breast cancer cells, and when the non-gotinib is used in combination with JQ1, GPX4 over-expression cells which are resistant to the JQ1 restore the sensitivity to the JQ1, and the result shows that the non-gotinib can enhance the sensitivity of the triple negative breast cancer cells to the JQ1 and can be used as a sensitizer of the JQ 1.
A second aspect of the invention provides any one of the following applications:
(1) Use of non-golitinib for the preparation of a medicament for increasing the sensitivity of a triple negative breast cancer cell against a triple negative breast cancer medicament BBDI, said triple negative breast cancer medicament BBDI being JQ1 described in the first aspect of the invention;
(2) Use of a combination of non-golitinib and an anti-triple negative breast cancer drug BBDI for the preparation of a medicament for the treatment and/or prophylaxis of triple negative breast cancer, said anti-triple negative breast cancer drug BBDI being JQ1 as described in the first aspect of the invention;
(3) Use of an agent that inhibits the expression level of GPX 4in the preparation of a sensitizer for an anti-triple negative breast cancer drug BBDI, wherein the anti-triple negative breast cancer drug BBDI is JQ1 described in the first aspect of the present invention.
In the present invention, the information of GPX4 is as follows: gene ID of Gene GPX4 (glutathione peroxidase 4) is 2879, details of which are available in NCBI database (https:// www.ncbi.nlm.nih.gov/Gene /) based on the above Gene ID.
In some embodiments, the agent that inhibits the expression level of GPX4 includes, but is not limited to: agents that inhibit the expression of or reduce the expression level of a gene encoding a GPX4 protein, reduce the activity of a GPX4 protein, e.g., agents that inhibit the expression of or reduce the expression level of a GPX4 gene, include, but are not limited to: an agent that inhibits the transcriptional activity of the GPX4 gene, an agent that inhibits the transcriptional level of GPX4 mRNA, an agent that promotes the degradation of GPX4 mRNA, an siRNA directed against the GPX4 gene, an shRNA directed against the GPX4 gene, an agent that inhibits the translation of GPX4 mRNA, an agent that specifically recognizes and cleaves a targeting nucleic acid of the GPX4 gene to reduce its expression level, a dsRNA directed against the GPX4 gene, a microRNA directed against the GPX4 gene, an antisense nucleic acid directed against the GPX4 gene.
In other embodiments, inhibition or reduction of GPX4 gene expression may be achieved by knockdown of the GPX4 whole gene by administration of a targeting vector. In other embodiments, the agent that reduces GPX4 protein activity may be, for example, a specific antibody that targets GPX4 or a small molecule compound that has the activity of inhibiting GPX4 protein.
In a third aspect, the invention provides a pharmaceutical composition for combating triple negative breast cancer.
Further, the pharmaceutical composition comprises non-gotinib and an anti-triple negative breast cancer drug BBDI, wherein the anti-triple negative breast cancer drug BBDI is JQ1 described in the first aspect of the invention.
Further, the concentration ratio of the regorafenib and the anti-triple negative breast cancer drug BBDI is (40 μm-320 μm): (5. Mu.M-50. Mu.M).
Further, the pharmaceutical composition also comprises pharmaceutically acceptable carriers and/or auxiliary materials.
Further, the pharmaceutical composition is a single compound preparation or a combination of two independent single preparations.
Further, the compound preparation is a compound preparation containing the non-goiter and an anti-triple negative breast cancer drug BBDI;
Further, the combination of the single formulation is a combination of a single formulation comprising the non-golitinib and a single formulation comprising the anti-triple negative breast cancer drug BBDI.
In some embodiments, pharmaceutically acceptable carriers and/or excipients described herein include, but are not limited to: diluents, binders, surfactants, wetting agents, adsorption carriers, lubricants, fillers, disintegrants.
In particular embodiments, the diluents include, but are not limited to: lactose, sodium chloride, glucose, urea, starch, water, etc. The adhesive includes, but is not limited to: starch, pregelatinized starch, dextrin, maltodextrin, sucrose, acacia, gelatin, methylcellulose, hydroxypropyl methylcellulose, and the like. The surfactants include, but are not limited to: polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, glyceryl monostearate, cetyl alcohol, etc. The wetting agents include, but are not limited to: glycerol, starch, and the like. The adsorbent carrier includes, but is not limited to: starch, lactose, bentonite, silica gel, kaolin, bentonite, etc. The lubricant includes, but is not limited to: zinc stearate, glyceryl monostearate, polyoxyethylene monostearate, monolauryl saccharate, sodium lauryl sulfate, magnesium lauryl sulfate, etc. The filler includes, but is not limited to: mannitol, xylitol, sorbitol, maltose, erythrose, glucose, lactose, sucrose. Such disintegrants include, but are not limited to: crosslinked vinylpyrrolidone, sodium carboxymethyl starch, low-substituted hydroxypropyl methyl, crosslinked sodium carboxymethyl cellulose, soybean polysaccharide, etc.
In some embodiments, the pharmaceutical compositions of the present invention may further comprise additives such as stabilizers, buffers, bactericides, isotonic agents, pH controlling agents, surfactants, and chelating agents. The choice of the above-mentioned agents is not particularly limited in the present invention, and any pharmaceutical composition containing the regorafenib and the anti-triple negative breast cancer drug BBDI as main active ingredients is within the scope of the present invention.
In some embodiments, the pharmaceutical compositions of the present invention may also be used in combination with other therapeutic compounds that can be used to treat triple negative breast cancer, which may be administered simultaneously with the primary active ingredient in the pharmaceutical compositions of the present invention, even in the same composition. Other therapeutic compounds may also be administered alone, in separate compositions or in a dosage form different from the primary active ingredient. A partial dose of the main ingredient may be administered simultaneously with the other therapeutic compounds, while the other doses may be administered separately. The dosage of the pharmaceutical composition of the present invention may be adjusted during the course of treatment according to the severity of the symptoms, the frequency of recurrence and the physiological response of the treatment regimen.
In some embodiments, the other therapeutic compounds include, but are not limited to: chemotherapeutic agents, in particular, include, but are not limited to: taxane (paclitaxel, docetaxel, cabazitaxel), antibiotic (doxorubicin, epirubicin, daunorubicin, pirarubicin, etoposide, irinotecan, mitoxantrone), antimetabolite (cisplatin, carboplatin, lobaplatin, nedaplatin, oxaliplatin, gemcitabine, 5-fluorouracil), alkylating agent (cyclophosphamide, ifosfamide).
In a fourth aspect, the invention provides a pharmaceutical formulation for combating triple negative breast cancer.
Further, the pharmaceutical formulation comprises the pharmaceutical composition according to the third aspect of the present invention.
Further, the dosage forms of the pharmaceutical preparation include injection dosage forms, respiratory tract dosage forms, mucosa dosage forms and/or skin dosage forms.
Further, the injection administration type includes: intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection, and intracavitary injection.
Further, the respiratory tract administration dosage form includes: spray, aerosol, powder spray and other forms.
Further, the mucosal administration form includes: eye drops, nasal drops, eye ointments, gargle, sublingual tablet, adhesive tablet, patch, etc.
Further, the skin administration form includes: various dosage forms such as solution, lotion, liniment, ointment, plaster, paste, patch, etc.
In some embodiments, the dosage forms of the pharmaceutical formulations of the present invention are dosage forms that are convenient for administration prepared by conventional methods, including, but not limited to: parenteral dosage forms, specific examples include, but are not limited to: aqueous injection, powder for injection, pill, powder, tablet, patch, suppository, emulsion, cream, gel, granule, capsule, aerosol, spray, powder fog agent, sustained release agent, controlled release agent, etc.
In some embodiments, the pharmaceutical formulation includes pharmaceutical excipients that are conventionally used in a variety of formulations, including, but not limited to: isotonic agents, buffers, flavoring agents, excipients, fillers, binders, disintegrants, lubricants, and the like; may also be selected for use in response to the substance, including but not limited to: emulsifying agent, solubilizer, bacteriostat, analgesic, antioxidant, etc.
The auxiliary materials can effectively improve the stability and the solubility of the active ingredients contained in the composition or change the release rate, the absorption rate and the like of the active ingredients, thereby improving the metabolism of various active ingredients in organisms and further enhancing the administration effect of the composition. In addition, specific purposes or modes of administration may be achieved, such as: sustained release administration, controlled release administration, pulsatile administration, and the like, and adjuvants used include, but are not limited to: gelatin, albumin, chitosan, polyether and polyester polymer materials (such as polyethylene glycol, polyurethane, polycarbonate and copolymers thereof). The main manifestations of the beneficial drug administration are: improving the treatment effect, improving the bioavailability, reducing toxic and side effects, improving the compliance of patients and the like.
In some embodiments, the pharmaceutical composition or pharmaceutical formulation of the present invention may be suitably administered in various amounts depending on the formulation method, the administration mode, the age, weight, sex, disease state, diet, administration time, administration route, excretion rate and response sensitivity of the patient, and the like, and the skilled practitioner will generally be able to easily determine the prescription and the desired therapeutically effective dose, as long as it is capable of producing the desired therapeutic and/or prophylactic effect on triple negative breast cancer, and such doses are within the scope of the present invention.
In a fifth aspect, the invention provides a method for increasing sensitivity of a triple negative breast cancer cell to an anti-triple negative breast cancer drug BBDI in an in vitro non-therapeutic setting.
Further, the method comprises the following steps: adopting non-gotinib to treat a triple negative breast cancer cell culture system containing a triple negative breast cancer resistant drug BBDI;
the anti-triple negative breast cancer drug BBDI is JQ1 described in the first aspect of the present invention.
The invention also provides a method for treating triple negative breast cancer, which comprises the following steps: administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition or pharmaceutical formulation provided herein.
In some embodiments, the pharmaceutical composition or pharmaceutical formulation may be administered to the subject by injection, topical administration, or oral administration. For example, the method may comprise administering the pharmaceutical composition or pharmaceutical formulation to the subject three times a day, once every two days, and the like. In some embodiments, the administration by injection may include subcutaneous injection, intramuscular injection, intravenous injection, and the like. In some embodiments, injection administration may include injecting the pharmaceutical composition directly into the lesion or an area near the lesion, and in some embodiments, topical administration may include rectal administration, nasal administration, aural administration, intramedullary administration, intra-articular administration, intrapleural administration, and the like, or any combination thereof. In some embodiments, the pharmaceutical composition or pharmaceutical formulation may be administered to a subject via a combination of different modes of administration.
Compared with the prior art, the invention has the advantages and beneficial effects that:
According to the invention, the regorafenib can be used as a sensitizer for the anti-triple-negative breast cancer drug BBDI (JQ 1) for the first time, experiments prove that the regorafenib can obviously increase the sensitivity of triple-negative breast cancer cells to the anti-triple-negative breast cancer drug JQ1, reduce the drug resistance of the triple-negative breast cancer cells to the anti-triple-negative breast cancer drug JQ1, enhance the cytotoxicity and the killing effect of the anti-triple-negative breast cancer drug JQ1 to tumor cells, has good potential of developing into the sensitizer for the anti-triple-negative breast cancer drug JQ1, provides a brand-new thought and strategy for the field of developing the triple-negative breast cancer therapeutic drug, and has good clinical application prospect.
Drawings
Fig. 1: overexpression of GPX4 resulted in JQ1 resistance, wherein, panel a: relative mRNA expression levels of GPX4 in the GPX4 over-expression group and the empty vector control group; b, drawing: relative mRNA expression levels of GPX4 in the GPX4 silencing group and the empty vector control group; c, drawing: western Blotting results for GPX4 overexpression and silencing groups; d, drawing: western Blotting quantification of GPX4 overexpression and silencing groups; e, drawing: CCK8 assay results (24 hours of treatment) for JQ1 inhibition in GPX4 over-expression and empty vector control groups; f, drawing: IC50 values for JQ1 in GPX4 over-expression and empty vector control; graph G: CCK8 test results of JQ1 inhibition in GPX4 silencing group and empty vector control group; drawing H: IC50 values of JQ1 in GPX4 silenced and empty vector control, data expressed as mean ± standard deviation, significance in panels a and E-F were calculated using unpaired sample T-test (n=3), significance in panels B, D and G-H were calculated using one-way analysis of variance (n=3);
Fig. 2: JQ1 and regatinib in combination reverse JQ1 resistance, wherein, figure A: relative mRNA expression levels of GPX4 in the non-golitinib (160 μm,24 h) treated group and untreated Vector group; b, drawing: relative mRNA expression levels of GPX4 in the non-golitinib (160 μm,24 h) treated group and the untreated GPX4 overexpressed group; c, drawing: western Blotting results of GPX4 in the non-golitinib (160. Mu.M and 320. Mu.M, 24 h) treated Vector and GPX4 overexpressing group; d, drawing: western Blotting quantification of GPX4 in non-golitinib (160. Mu.M and 320. Mu.M, 24 h) treated Vector and GPX4 overexpressing groups; e, drawing: cell viability of Vector and GPX4 overexpressed SUM159 cells 24 hours after non-golitinib treatment; F-G diagram: CCK8 assay (24 hours) of JQ1 inhibition in Vector and GPX4 overexpressing groups (treated or untreated non-gotinib, respectively), data representing mean ± standard deviation, significance in a-B, E panels was calculated using unpaired sample T test (n=3), significance in D, F-G panels was calculated using one-way analysis of variance (n=3);
Fig. 3: JQ1 and regatinib in combination reverse JQ1 resistance, wherein, figure A: colony formation experiments of SUM159 cells in Vector and GPX4 overexpressing groups (with or without JQ1, regoratinib, or a combination of both); b, drawing: quantitative comparison of colony formation experiments in GPX4 over-expression group and Vector group (JQ 1 5. Mu.M, 10. Mu.M and 15. Mu.M, respectively); c, drawing: quantitative comparison of colony formation experiments in Vector group with non-golitinib treated (40. Mu.M), D-F panels: quantitative comparisons of colony formation experiments in the combination of JQ1 (5 μm,10 μm and 15 μm) or JQ 1-non-golitinib (40 μm) were treated separately in GPX4 overexpressing cells, data representing mean ± standard deviation, significance in C-F panels was calculated using unpaired sample T-test (n=3), significance in B panels was calculated using one-way analysis of variance (n=3).
Detailed Description
The inventor of the invention has conducted intensive research on the drug resistance of the triple negative breast cancer drug JQ1 through a single cell RNA sequencing technology, revealed dynamic changes of triple negative breast cancer cells, wherein the changes comprise transcriptome reprogramming, difference of cell composition and change of cell cycle state, the research has found that the correlation between JQ1 drug resistance and iron death inhibition is achieved, and further has found that the regoratinib can remarkably increase the sensitivity of the triple negative breast cancer cells to the triple negative breast cancer drug JQ1, enhance the cytotoxicity and killing effect of the triple negative breast cancer drug JQ1 to tumor cells, and have good potential of developing sensitizer of the triple negative breast cancer drug JQ 1. In order to facilitate an understanding of the present invention, the following terms referred to in the present invention are explained herein:
as used herein, the term "JQ1" is a BET bromodomain inhibitor having the molecular formula C 23H25ClN4O2 S and a molecular weight of 456.988, and the structural formula is shown in formula (I) above, and the term "JQ1" includes salts, esters, analogs, prodrugs and derivatives thereof.
As used herein, the term "regoratinib" is an oral, ATP-competitive, reversible JAK1 inhibitor, and the term "JQ1" includes salts, esters, analogs, prodrugs and derivatives thereof.
As used herein, the term "pharmaceutically acceptable carrier and/or adjuvant" is well documented in Remington's Pharmaceutical Sciences (19 th ed, 1995) which is used as needed to aid stability of a drug or to aid in enhancing the activity of an active ingredient in a drug, which may be used in such a pharmaceutical composition in the form of its original compound itself, or optionally in the form of a pharmaceutically acceptable salt thereof, and the pharmaceutical composition so formulated may be administered as needed by any suitable means known to those skilled in the art.
In some embodiments, the pharmaceutically acceptable carrier and/or adjuvant may additionally contain liquids such as water, physiological saline, glycerol, and ethanol. In addition, auxiliary substances such as wetting or emulsifying agents or pH buffering substances may be present in the composition. These carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries and suspensions, for ingestion by a patient.
As used herein, the term "treatment" refers to the inhibition, containment, alleviation, amelioration, slowing, stopping, delaying or reversing of the progression or exacerbation of a disease in order to prevent or reduce the occurrence or progression of the disease, and the various indicators of the disease, disorder or pathological state described as maintaining and/or administering include alleviation or reducing the symptoms or complications of a particular disease, or curing or eliminating the disease, disorder or condition. In a specific embodiment of the invention, the disease is preferably triple negative breast cancer.
As used herein, the term "prevention" refers to various means or measures, including medical, physical or chemical methods, for preventing the occurrence or progression of a disease, preferably triple negative breast cancer, prior to the disease not being recognized by clinical criteria, to prevent and reduce the occurrence or progression of various symptoms of the disease.
As used herein, the term "therapeutically effective amount" refers to an amount that produces a therapeutic effect on and is acceptable to a human and/or animal. For example, a pharmaceutically or pharmaceutically effective amount refers to the amount of drug required to produce a desired therapeutic effect, which can be reflected by the results of a clinical trial, a model animal study, and/or an in vitro study. The pharmaceutically effective amount depends on several factors, including but not limited to: the characteristic factors of the subject (such as the subject's height, weight, sex, age, and history of administration), the severity of the disease.
The pharmaceutical active ingredients (non-gotinib, anti-triple negative breast cancer drug JQ 1) described in the present invention and pharmaceutically acceptable carriers and/or excipients (carriers for therapeutic administration and/or carriers, which are not themselves essential active ingredients and which have no excessive toxicity after administration) may constitute a pharmaceutical composition or pharmaceutical formulation. In particular embodiments of the invention, the "therapeutically effective amount" refers to an amount sufficient to inhibit, slow or prevent triple negative breast cancer occurrence and progression in a subject.
As used herein, the term "active ingredient" refers to the component of a pharmaceutically acceptable composition that is responsible for the therapeutic effect of the composition, while the other components of the composition (e.g., excipients, carriers, and diluents) are not responsible for the therapeutic effect of the composition, even though they have other functions in the composition that are necessary or desirable as part of a formulation (e.g., lubrication, flavoring, pH control, emulsification, stabilization, preservation, and other functions in addition to the therapeutic effect of the composition as described herein).
As used herein, the term "administering," when applied to an animal, human, subject, cell, tissue, organ, or biological fluid, refers to contacting an exogenous drug, pharmaceutical composition, or pharmaceutical formulation with the animal, human, subject, cell, tissue, organ, or biological fluid. "administration" may refer to, for example, therapeutic, pharmacokinetic, diagnostic, research, and experimental methods. Treatment of the cell includes contacting the reagent with the cell and contacting the reagent with a fluid. "administration" also means the in vitro and ex vivo treatment of cells by an agent, composition or by another cell, and when the "treatment" is applied to a human, veterinary or research subject, means therapeutic treatment, prophylactic or preventative measures, research and diagnostic application.
As used herein, the term "subject" refers to any animal, and also refers to human and non-human animals. Non-human animals include all vertebrates, for example, mammals, such as non-human primates (particularly higher primates), sheep, dogs, rodents (such as mice or rats), guinea pigs, goats, pigs, cats, rabbits, cattle, and any domestic animals or pets; and non-mammals such as chickens, amphibians, reptiles, and the like. In a specific embodiment of the invention, the subject is preferably a human.
The invention is further illustrated below in conjunction with specific examples, which are provided solely to illustrate the invention and are not to be construed as limiting the invention. One of ordinary skill in the art can appreciate that: many changes, modifications, substitutions and variations may be made to the embodiments without departing from the spirit and principles of the invention, the scope of which is defined by the claims and their equivalents.
The drugs, reagents and raw materials used in the present invention are readily available to those of ordinary skill in the art, and unless otherwise indicated, are commercially available, and the experimental methods of the present invention without specifying the specific conditions are usually carried out according to conventional conditions or according to conditions suggested by the manufacturer, and in particular, the following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the present invention in any way.
Example use of regatinib as sensitizer for anti-triple negative breast cancer drug BBDI (JQ 1)
1. Experimental materials
Human triple negative breast cancer cell lines SUM159 were purchased from Gibco (America) with Ham's F medium, from Millipore (Israel), from Selleck (America), from Sigma (America), from insulin and hydrocortisone, from Shanghai Ji Ma (China), from SiRNA packages, from Shangzhou Ruibo (China), from FastPure cells/tissue Total RNA extraction kit V2, HISCRIPTEIII RT reverse transcription reagent, from SYBR Green, from Novozan (China), from BCA protein quantification kit from Biyuna (China), from Millipore (America) with PVDF film, from Abcam (America) with GPX4 antibody, from GAPDH (America) from Proteintech (America), from MCE (America) with anti-triple negative breast cancer drug JQ1, and from HY-13030.
2. Experimental method
(1) Cell culture
SUM159 cells were cultured in a combined medium (Ham's F) containing 5% FBS, 5. Mu.g/mL insulin and 1. Mu.g/mL hydrocortisone at 37℃in a 5% carbon dioxide incubator.
(2) CCK8 experiment
SUM159 cells were seeded in 96-well plates and cultured for 24 hours. The original medium was replaced with a medium containing the indicated drug mixture. After 24 or 48 hours, CCK-8 solution was added to the wells and the 96-well plates incubated at 37℃for 3.5 hours. Optical Density (OD) values were measured using an ELISA plate reader and the system analysis determined the cell inhibition rate.
(3) Cell transfection
SUM159 cells were seeded at a density of 2 x 10 5 cells per well in 6-well plates and incubated overnight. The culture medium is replaced by a fresh culture medium, and GPX4 over-expression lentivirus (Shanghai Ji Ma company) with the titer of 10 9 is added, the control lentivirus with the titer of 10 8 is added with the concentration of 10 [ mu ] L, and the culture is carried out in a 5% carbon dioxide box at 37 ℃ for 48 hours with the concentration of the virus infection reagent HITRANSG A [ mu ] L. The transfection was transferred into a cell culture flask, screened with puromycin under pressure for two weeks, and the effect of transfection was evaluated by RT-qPCR and Western blotting.
SUM159 cells were seeded at a density of 1 x 10 5 cells per well in 24 well plates and incubated overnight. The medium was replaced with fresh medium and three GPX4 knockdown siRNAs (Hibiscus sabdariffa, ruibo Biotechnology Co., ltd.) were transfected individually with riboFECT TM CP REAGENT in 24 well plates to a final transfection concentration of 50 nM. The transfection effect is evaluated by RT-qPCR and Western blotting after 24 hours of culture in a 5% carbon dioxide box at 37 ℃, and three GPX4 knockdown siRNAs have better knockdown efficiency, and in the embodiment, the siRNA-1 and siRNA-2 with the best knockdown efficiency are selected for subsequent experiments. Wherein the sequences of the three GPX4 knockdown siRNAs are shown below, respectively.
siRNA-1:5'-GCTACAACGTCAAATTCGA-3'(SEQ ID NO:5);
siRNA-2:5'-GTAACGAAGAGATCAAAGA-3'(SEQ ID NO:6);
siRNA-3:5'-GAGGCAAGACCGAAGTAAA-3'(SEQ ID NO:7)。
(4) Colony formation experiments
SUM-159 cells were packed in 6-well plates at a density of 800 cells per well and cultured for 10 days. Subsequently, cells were fixed with 1 mL methanol per well and stained with 0.1% crystal violet solution. Photographs of the stained colonies were taken and the colony results were quantitatively analyzed using Image J software.
(5) RT-qPCR analysis
Total RNA was extracted and reverse transcribed into synthetic cDNA using 1. Mu.g RNA. Fluorescence quantitative PCR was performed using SYBR Green. The primers for GPX4 are respectively:
F:5'-CCCAGTGAGGCAAGACCGAAG-3'(SEQ ID NO:1);
R:5'-GGCTCCTGCTTCCCGAACTG-3'(SEQ ID NO:2)。
The primers for the reference gene GAPDH were:
F:5'-CGGAGTCAACGGATTTGGTCG-3'(SEQ ID NO:3);
R:5'-TCTCGCTCCTGGAAGATGGTGAT-3'(SEQ ID NO:4)。
PCR results were recorded as cycle threshold (Ct) and normalized to internal control (GAPDH).
(6)Western blot
The cells were collected and lysed and the supernatant centrifuged and stored frozen at-80℃until further use. The BCA kit was used to quantify total protein concentration. SDS-PAGE gel electrophoresis, proteins were transferred to PVDF membrane. 5% nonfat milk powder was incubated overnight at 4℃in a dilution containing primary antibody. Then, the mixture was incubated with the secondary antibody at room temperature for 1 hour. The protein bands were visualized using chemiluminescent substrates and the results were analyzed by Image J software.
3. Experimental results
(1) Overexpression of GPX4 leads to JQ1 resistance
The inventors of the present invention have found a correlation between JQ1 resistance and iron death inhibition through a large number of studies in the early stage. GPX4 as an important iron death regulator, we examined the correlation of its expression level with JQ1 resistance. First, a SUM159 cell line was established for GPX4 overexpression and silencing (FIGS. 1A-D). Subsequently, the sensitivity of these cell lines to JQ1 was assessed. The GPX4 over-expression group significantly reduced the JQ1 inhibition rate (fig. 1E) and the half maximal inhibitory concentration (IC 50) of JQ1 was increased at 24 hours and 48 hours (fig. 1F) compared to the empty vector group. In contrast, GPX 4-silenced cells exhibited higher JQ1 inhibition and reduced IC50 (fig. 3G-H), indicating increased sensitivity of the cells to JQ 1. These results demonstrate a key role for GPX4 in mediating JQ1 resistance, demonstrating its potential as a target for therapeutic intervention.
(2) Combination of regatinib and JQ1 can reverse JQ1 resistance
We examined the effect of regorafenib on GPX4 mRNA and protein levels and found that regorafenib significantly reduced GPX4 mRNA and protein levels in the control and GPX4 over-expression groups (fig. 2A-D). Next we explored the cytotoxic effect of regorafenib and found that after 24 hours and 48 hours of high dose regorafenib treatment, there was no significant difference in the activity of the experimental group compared to the control group cells (fig. 2E), indicating that the cytotoxic effect of regorafenib on the triple negative breast cancer cells was minimal, while indicating that regorafenib alone had no significant inhibitory effect on the triple negative breast cancer cells. GPX4 over-expressing cells resistant to JQ1 restored sensitivity to JQ1 when non-golitinib was used in combination with JQ 1. After 24 hours and 48 hours of the joint treatment of regoratinib (160 μm and 320 μm) with JQ1, the IC50 value of JQ1 in the GPX4 over-expression group was reduced, and the cell growth inhibitory effect was remarkable (fig. 2F-G). Colony formation experiments showed that the GPX4 over-expressed group had more cell colonies at different doses of JQ1 (5. Mu.M, 10. Mu.M and 15. Mu.M) (FIGS. 3A-B), which also indicated that GPX4 over-expression resulted in JQ1 resistance. The colony numbers were not significantly altered by regoratinib alone (fig. 3C), however, the combination therapy of JQ1 and regoratinib significantly reduced the cell colony numbers in the GPX4 over-expression group compared to JQ1 alone (fig. 3D-F). The results show that the regorafenib can enhance the sensitivity of the triple negative breast cancer cells to JQ1, in conclusion, the research of the research confirms that the small molecular regorafenib is used as a potential enhancer of the sensitivity of JQ1 in the JQ1 resistant cells, and provides new insight for developing an alternative treatment method to reduce the resistance of the triple negative breast cancer cells to JQ 1.
Claims (10)
1. The application of the non-gotinib in preparing the sensitizer of the anti-triple negative breast cancer drug BBDI is characterized in that the anti-triple negative breast cancer drug BBDI is JQ1, and the structural formula of the JQ1 is shown as the formula (I):
Formula (I).
2. The use according to claim 1, wherein the non-goitinib is capable of increasing the sensitivity of triple negative breast cancer cells to the anti-triple negative breast cancer drug BBDI.
3. The use according to claim 1, wherein overexpression of GPX4 in triple negative breast cancer cells results in its resistance to the triple negative breast cancer drug BBDI.
4. The use according to claim 1, characterized in that the concentration ratio of the regorafenib and the anti-triple negative breast cancer drug BBDI is (40 μΜ -320 μΜ): (5. Mu.M-50. Mu.M).
5. An application according to any one of the following, characterized in that the application comprises:
(1) Use of non-golitinib for the preparation of a medicament for increasing the sensitivity of a triple negative breast cancer cell against a triple negative breast cancer drug BBDI, said triple negative breast cancer drug BBDI being JQ1 as described in claim 1;
(2) Use of a combination of non-golitinib and an anti-triple negative breast cancer drug BBDI for the preparation of a medicament for the treatment and/or prophylaxis of triple negative breast cancer, said anti-triple negative breast cancer drug BBDI being JQ1 as defined in claim 1;
(3) Use of an agent that inhibits the expression level of GPX4 in the preparation of a sensitizer for an anti-triple negative breast cancer drug BBDI, wherein the anti-triple negative breast cancer drug BBDI is JQ1 as described in claim 1.
6. A pharmaceutical composition for anti-triple negative breast cancer, comprising non-gotinib and an anti-triple negative breast cancer drug BBDI, wherein the anti-triple negative breast cancer drug BBDI is JQ1 as defined in claim 1.
7. The pharmaceutical composition according to claim 6, characterized in that the concentration ratio of the regorafenib and the anti-triple negative breast cancer drug BBDI is (40 μΜ -320 μΜ): (5. Mu.M-50. Mu.M).
8. A pharmaceutical formulation against triple negative breast cancer, characterized in that it comprises the pharmaceutical composition of claim 6 or 7.
9. The pharmaceutical formulation of claim 8, wherein the dosage form of the pharmaceutical formulation comprises an injectable dosage form, a respiratory administration dosage form, a mucosal administration dosage form, and/or a dermal administration dosage form.
10. A method of increasing sensitivity of a triple negative breast cancer cell to an anti-triple negative breast cancer drug BBDI at an in vitro non-therapeutic destination, the method comprising the steps of: adopting non-gotinib to treat a triple negative breast cancer cell culture system containing a triple negative breast cancer resistant drug BBDI;
The anti-triple negative breast cancer drug BBDI is JQ1 described in claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410809482.9A CN118593509A (en) | 2024-06-21 | 2024-06-21 | Application of non-gotinib as sensitizer of anti-triple negative breast cancer drug BBDI |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410809482.9A CN118593509A (en) | 2024-06-21 | 2024-06-21 | Application of non-gotinib as sensitizer of anti-triple negative breast cancer drug BBDI |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118593509A true CN118593509A (en) | 2024-09-06 |
Family
ID=92553367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410809482.9A Pending CN118593509A (en) | 2024-06-21 | 2024-06-21 | Application of non-gotinib as sensitizer of anti-triple negative breast cancer drug BBDI |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118593509A (en) |
-
2024
- 2024-06-21 CN CN202410809482.9A patent/CN118593509A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11839591B2 (en) | Pharmaceutical combination for the treatment of melanoma | |
EA015560B1 (en) | Method of treating viral hepatitis | |
KR102358632B1 (en) | Composition for preventing or treating colon cancer comprising streptonigrin and anticancer agent | |
WO2023092943A1 (en) | Use of dronedarone hydrochloride in combination with 5-fluorouracil in preparation of anti-tumor drug | |
CN117942345A (en) | Method for treating NUT cancer by using ARV-825 molecular ligand | |
CN118593509A (en) | Application of non-gotinib as sensitizer of anti-triple negative breast cancer drug BBDI | |
WO2020181802A1 (en) | Effective anti-malignant tumor rpharmaceutical composition and application thereof | |
KR102401604B1 (en) | New uses for desmethylclozapine | |
CN111686111B (en) | Application of MALT1 protease inhibitor in preparation of non-small cell lung cancer therapeutic drug | |
RU2623142C2 (en) | Intravesical apaziquone injection after transurethral resection for cancer treatment | |
US20220313652A1 (en) | Use of compound or pharmaceutically acceptable salt, dimer or trimer thereof in manufacture of medicament for treating cancer | |
US20220323470A1 (en) | Composition and use thereof in the manufacture of medicament for treating cancer | |
WO2024193693A1 (en) | Pharmaceutical composition and use thereof | |
CN113633631B (en) | Application of miboplatin liposome in drug-resistant tumor resistance | |
US20190247416A1 (en) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis | |
CN118236369B (en) | Application of atractylenolide III in preventing and treating diarrhea caused by tyrosine kinase inhibitor | |
CN118846078A (en) | Application of NDRG2 gene combined molecular targeting inhibitor in preparation of renal cell carcinoma therapeutic drug | |
CN118436641A (en) | Application of compound CBR-5884 in preparation of ovarian cancer stem cell proliferation inhibitor | |
TW202404611A (en) | Methods of treating inflammation | |
CN116327772A (en) | Targeting treatment method for bone metastasis of SMO inhibitor Sonidegib to tubular breast cancer | |
CN114984004A (en) | Application of sulcardine sulfate in preparation of anti-sepsis medicine | |
CN113633638A (en) | Application of LY2835219 in preparation of anti-tumor metastasis drugs | |
EP4452989A1 (en) | Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis | |
JP2021020875A (en) | Cancer stem cell self-replication inhibitor and stat3 phosphorylation inhibitor | |
EP4340832A1 (en) | Method of treating rna repeat mediated diseases with rna repeat binding compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |